Please assess the completion status of the following clinical trial:

Trial Title: High Dose PPI Triple Therapy Versus Sequential Therapy for Helicobacter Pylori Eradication

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Functional dyspepsia patients (Rome III) with rapid urease test positive~* Age ≥ 18 years old~* No history of HP eradication~Exclusion Criteria:~* Recent use of PPI, H2RA, NSAID, Antibiotics within 2 weeks~* Currently use of anticoagulants or ketoconazole~* C/I for gastric biopsy~* History of gastric surgery~* Comorbidity: ESRD, advanced cirrhosis, AIDS, stroke (bed ridden)~* Pregnancy or lactation~* Allergy to studied drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sequential therapy (ST) (Type: ACTIVE_COMPARATOR): 10 day Sequential therapy: lansoprazole 30 mg b.d. plus amoxicillin 1000 mg b.d. for 5 days then lansoprazole 30 mg b.d., metronidazole 400 mg b.d. and clarithromycin 500 mg b.d. for the remaining 5 days
- High dose PPI triple therapy(TT) (Type: EXPERIMENTAL): 10 day high dose PPI triple therapy: lansoprazole 60 mg b.d. plus clarithromycin 500 mg b.d. and amoxycillin 1000 mg b.d. for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).